IN THE CLAIMS:

1. (Cancel)

2. (Cancel)

3. (Cancel)

4. (Cancel)

5. (Cancel).

6. (Cancel)

7. (Currently Amended) DNA sequence encoding ~~a product according to one of Claims 1 to 6~~ an adjuvant comprising at least the fragment of the P40 protein *Klebsiella pneumoniae*, said fragment having the amino acid sequence of SEQ ID No: 8.

8. (Cancel)

9. (Cancel)

10. (Cancel)

11. (Cancel)

12. (Currently Amended) ~~Process~~ A process for increasing the immunogenicity of an antigen or a hapten, ~~characterized in that the~~ comprising the step of attaching said antigen or hapten ~~is attached~~ to an adjuvant, ~~according to one of Claims 1 to 6 in the form of a complex according to one of Claims 8 to 11~~ wherein said adjuvant improves the immune response of an antigen or hapten when administered to a host, and wherein said adjuvant has at least one fragment of the P40 protein of *Klebsiella pneumoniae*, or a protein having at least 80% amino acid identity degree after alignment with the P40 protein of *Klebsiella pneumoniae*.

13. (Currently Amended) ~~Process~~ The process ~~according to~~ of claim 12 ~~characterized in that the~~ wherein said antigen or hapten is attached to ~~the~~ said adjuvant by chemical coupling.

14. (Currently Amended) ~~Process~~ The process ~~according to one of Claims 12 or 13, characterized~~ of claim 12 ~~in that the~~ wherein said antigen or hapten is fused to ~~the~~ said adjuvant by genetic manipulation.

15. (Cancel)

16. (Currently Amended) ~~DNA sequence according to~~ A pharmaceutical composition comprising said DNA sequence ~~to~~ of claim 7~~, as a medicament~~ and a pharmaceutically acceptable carrier.

17. (Currently Amended) ~~Use of a~~ A vaccine for intramuscular or intradermal administration comprising said DNA sequence ~~according to Claim 7 for preparing a vaccine to be used by the intramuscular or intradermal route~~ of claim 7.

18. (Cancel)